AN2 Therapeutics
antibacterial activity in a chronic model of mac lung disease in mice showed improved antibacterial activity of at all doses compared to the daily humanized dose of an therapeutics | AN2 Therapeutics
Deck date
August 2022
Slide
14 of 25
Similar slides by AN2 Therapeutics
Investor Presentation
August 2022
IPO
March 2022
IPO
March 2022
Related slides by other companies
Investor Day
April 2022
Other recent decks by AN2 Therapeutics
IPO
March 2022
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2023 Slidebook.io